Drug intelligence / Profile preview

BB1202

Development stage: Unknown
Lead developer: Blueberry Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

BB1202 is a topical antifungal spray formulation being developed by Blueberry Therapeutics for the treatment of tinea pedis (athlete's foot). It utilizes Blueberry's nanodelivery platform technology to enhance drug penetration into the upper layers of the skin. This approach aims to use significantly lower doses of an existing antifungal agent while matching efficacy and improving safety. The cutaneous spray solution offers advantages over currently available topical treatments, which often leave excess residue on the skin.

Beyond the preview

Go deeper on BB1202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB1202.

Explore the full profile